2015 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/17/2015OpGen's QuickFISH Rapid Pathogen ID Test Demonstrates Clinical Utility and Cost Effectiveness in Community Hospital’s Antimicrobial Stewardship Program
Published study documents annual savings at Winter Haven Hospital of more than $760,000 from use of the OpGen test, which resulted in a 30% reduction in patient length of stay and a 65% reduction in vancomycin use GAITHERSBURG, Md. , Dec. 17, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a molecular diagnostics and bioinformatics company helping to guide antibiotic therapy and to assist healthcare providers in combatting multi-drug resistant infections, announce... 
 Printer Friendly Version
11/18/2015District of Columbia Hospital Association Chooses OpGen to Create Citywide Effort to Track Multidrug-Resistant Bacteria
DC’s Public Health Agencies, Healthcare Facilities to Examine Occurrence of “Superbugs” in First-of-Its-Kind Evaluation, Supported by the Centers for Disease Control & Prevention GAITHERSBURG, Md. and WASHINGTON, Nov. 18, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) and the District of Columbia Hospital Association (DCHA) today announced that Washington DC’s public health departments will oversee a comprehensive citywide evaluation, HARP-DC (Healthcare facility Antibiotic Resistance... 
 Printer Friendly Version
11/12/2015OpGen Reports Third Quarter Financial Results and Provides Business Update
Conference Call Begins at 4:30 p.m. Eastern Time Today GAITHERSBURG, Md., Nov. 12, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an early commercial-stage company using molecular testing and bioinformatics to help guide antibiotic therapy and to assist healthcare providers combat multi-drug resistant infections, today reported financial results for the three and nine months ended September 30, 2015. Highlights of the third quarter of 2015 and recent weeks include: OpGen chosen to ... 
 Printer Friendly Version
11/04/2015OpGen, Inc. Announces Timing for Third Quarter Financial Results and Conference Call
GAITHERSBURG, Md., Nov. 4, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an early-stage commercial molecular testing and bioinformatics company, today announced that financial results for the company's third quarter ended September 30, 2015 will be released Thursday, November 12, 2015 following the close of market.   The management team will host a conference call discussing the company's financial results and recent developments on Thursday, November 12, 2015 at 4:30 p.m. E.T. The call ma... 
 Printer Friendly Version
10/12/2015Data Show “Super Bug” Surveillance System Based on OpGen’s Acuitas(R) Resistome Test Can Identify Potential Outbreaks in Hospitals and Improve Infection Control  
Researchers From Rush University Medical Center Present Data at IDWeek 2015 GAITHERSBURG, Md., Oct. 12, 2015 (GLOBE NEWSWIRE) --  OpGen, Inc. (NASDAQ:OPGN), an early-stage commercial molecular testing and bioinformatics company, today announced that new data from a study with its Acuitas® Resistome Test were presented on October 10 as an oral abstract at IDWeek 2015 by Michael Lin, M.D., M.P.H., an infectious disease physician and assistant professor of medicine at Rush University Medical Cen... 
 Printer Friendly Version
09/22/2015OpGen to Present Data Showing Acuitas(R) Tests are Effective Tools for Investigating Transmission of "Super Bugs"
Acuitas Resistome Test and Whole Genome Sequence Analysis Showcased at American Society for Microbiology Conference on Next Generation Sequencing for Epidemiologic Investigation of Pathogens GAITHERSBURG, Md., Sept. 22, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas® Resistome Test and Acuitas Whole Genome Sequence (WGS) Analysis for multidrug-resistant organisms (MDROs) will be presented at the American Society for Microbiology's First Conference on... 
 Printer Friendly Version
08/13/2015OpGen Reports Second Quarter Financial Results and Provides Business Update
Conference Call Begins at 4:30 p.m. Eastern Time Today GAITHERSBURG, Md., Aug. 13, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an early commercial-stage molecular testing and bioinformatics company, today reported financial results for the three and six months ended June 30, 2015. Highlights of the second quarter of 2015 and recent weeks include: Acquisition of AdvanDx, Inc., a market leader in rapid molecular testing for microorganism identification Completion of a $6 mil... 
 Printer Friendly Version
08/05/2015OpGen, Inc. Announces Timing for Second Quarter Financial Results and Conference Call
GAITHERSBURG, Md., Aug. 5, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), today announced that financial results for the company's second quarter ended June 30, 2015 will be released Thursday, August 13, 2015 following the close of market. The management team will host a conference call discussing the company's financial results and recent developments on Thursday, August 13, 2015 at 4:30 p.m. E.T. The call may be accessed by dialing (888) 883-4599 (domestic) or (484) 653-6821 (internationa... 
 Printer Friendly Version
07/14/2015OpGen Closes $6 Million Financing With Merck GHI to Expand Infectious Disease Diagnostic Testing Capabilities
David M. Rubin, Ph.D., Managing Director, Merck Global Health Innovation Fund, to Join OpGen Board of Directors GAITHERSBURG, Md., July 14, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced the closing of a $6 million financing by the Merck Global Health Innovation Fund (Merck GHI). In connection with this financing, David M. Rubin, Ph.D., Managing Director of Merck GHI, has been appointed to OpGen's board of directors, effective immediately. Evan Jones, chairman and chief ... 
 Printer Friendly Version
07/14/2015OpGen to Acquire AdvanDx, Inc.
Gains Rapid Molecular Diagnostic Tests and Additional Sales Channels Conference Call to Begin at 10:00 a.m. Eastern Time Today GAITHERSBURG, Md., July 14, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN), has agreed to acquire AdvanDx, Inc., a Woburn, Mass. developer of advanced molecular diagnostic products. The acquisition will be accounted for as a merger combination. The consummation of the merger provides OpGen with a family of FDA approved and CE marked rapid molecular tests for ... 
 Printer Friendly Version
07/13/2015Fluidigm and OpGen Enter Into Strategic Agreement to Develop Multi-Drug Resistance Testing Kits and Equipment
Five-Year Agreement Expands on Prior Supply Agreement SOUTH SAN FRANCISCO, Calif. and GAITHERSBURG, Md., July 13, 2015 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and OpGen, Inc. (NASDAQ:OPGN) today announced an expanded relationship and new agreement that includes collaborating on the development of test kits and custom analytic instruments for identification, screening, and surveillance testing of multi-drug resistance organism (MDRO) genes of pathogens, such as bacteria, fungi and... 
 Printer Friendly Version
06/17/2015OpGen Reports First Quarter Financial Results and Provides Business Update
GAITHERSBURG, Md., June 17, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN), an early commercial-stage molecular testing and bioinformatics company, today reported financial results for the three months ended March 31, 2015. Highlights of the first quarter of 2015 and recent weeks include: Completing a $17.1 million initial public offering (IPO) of common stock and warrants Strengthening the management team by adding Kevin Krenitsky, M.D. as president and Tim Dec as chief financ... 
 Printer Friendly Version
06/11/2015OpGen, Inc. Announces Timing for First Quarter Financial Results and Conference Call
GAITHERSBURG, Md., June 11, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN), today announced that financial results for the company's first quarter ended March 31, 2015 will be released Wednesday, June 17, 2015 following the close of market.   The management team will host a conference call discussing the company's financial results and recent developments on Wednesday, June 17, 2015 at 4:30 p.m. E.T. The call may be accessed by dialing (888) 883-4599 (domestic) or (484) 653-6821 (internation... 
Download PDFPrinter Friendly Version
06/02/2015OpGen Releases Next-Generation Molecular Testing and Bioinformatics Solution for Combating Multi-Drug Resistant Infections
- Company Participating in Today's White House Forum on Antibiotic Stewardship - Acuitas® Resistome, Acuitas Whole Genome Sequencing, and Acuitas Lighthouse™ MDRO Management System Now Available GAITHERSBURG, Md., June 2, 2015 (GLOBE NEWSWIRE) --  OpGen, Inc. (Nasdaq:OPGN), an early commercial-stage molecular testing and bioinformatics company, today launched its expanded, comprehensive molecular testing and bioinformatics program for detecting and managing Gram negative multi-drug res... 
Download PDFPrinter Friendly Version
05/27/2015OpGen's Acuitas(R) MDRO Gene Tests and Bioinformatics Data to be Presented at ASM2015
Posters and Presentations Highlight Performance of OpGen's Acuitas MDRO Products GAITHERSBURG, Md., May 27, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN), an early commercial stage molecular testing and bioinformatics company, today announced that new study data on its Acuitas® MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Lighthouse™ MDRO Management System will be presented at the 115th General Meeting of the American Society of Microbiology, to be held from May 30 to June 2 in New O... 
Download PDFPrinter Friendly Version
05/05/2015OpGen Announces Pricing of Initial Public Offering
GAITHERSBURG, Md., May 5, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN) today announced the pricing of its initial public offering of 2,850,000 units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock, at a combined price to the public of $6.00 per unit. All of the units are being offered by OpGen. OpGen's common stock and warrants have been approved for listing on the NASDAQ Capital Market. The units will immediately and automaticall... 
Download PDFPrinter Friendly Version
04/29/2015OpGen’s Acuitas® MDRO Gene Test Data Presented at 25th European Congress of Clinical Microbiology and Infectious Diseases
Results from the University of Maryland School of Medicine Demonstrate Acuitas MDRO Gene Test is a Highly Sensitive and Efficient Method for Detecting the Presence of Antibiotic Resistance Genes GAITHERSBURG, Md. (April 29, 2015) – OpGen, Inc., a molecular testing and bioinformatics company, today announced that new study data on its Acuitas® MDRO Gene Test was presented at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held from April 25th to 28th in Co... 
Download PDFPrinter Friendly Version
04/20/2015OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer
Expands executive team to support the rollout of antibiotic-resistant infection testing and bioinformatics platform, and to help ensure public company financial controls GAITHERSBURG, Md. (April 20, 2015) – OpGen, Inc., a molecular testing and bioinformatics company, today announced the expansion of its executive management team with the appointments of former Foundation Medicine (NASDAQ: FMI) executive Kevin Krenitsky, M.D. as president, and Timothy C. Dec as interim chief financial officer.... 
Download PDFPrinter Friendly Version
03/03/2015OpGen Files Registration Statement for Proposed Initial Public Offering
GAITHERSBURG, Md. (March 3, 2015)–OpGen, Inc. today announces the filing of its registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to its proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. OpGen is in the process of applying to list its common stock under the symbol “OPGN” on The NASDAQ Capital Market.Maxim Group LLC is acting as sole book-running man... 
Download PDFPrinter Friendly Version